As discussed above, the evidence for GLP‐1 RAs, dual GLP‐1/GIP RAs, and other incretin‐based therapies in HFrEF remains limited and inconclusive, with concerns about potential adverse effects such as arrhythmias and worsening HF. The gene discussed is GIP; the disease is hydrops fetalis.